

Trust Headquarters
 Russell's Hall Hospital
 Dudley
 West Midlands
 DY1 2HQ

Ref: FOI-022026-0002216

Date: 12.03.2026

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

I would greatly appreciate it if you could answer the following questions:

Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 5
- Amivantamab Monotherapy 0
- Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) 1
- Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel
- Atezolizumab monotherapy (subcutaneous injection only) 1
- Dabrafenib + Trametinib 0
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 1
- Durvalumab 1
- Gemcitabine 0
- Nintedanib + Docetaxel 1
- Nivolumab 0
- Osimertinib 20
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) 0
- Paclitaxel 0
- Pembrolizumab Monotherapy 21
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 3
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 3
- Pemetrexed + Platinum (Carboplatin/Cisplatin) 5
- RET Inhibitors (Pralsetinib, Selpercatinib) 0
- Sotorasib 0
- Tepotinib 2
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin 7
- Other active systemic anti-cancer therapy 18
- Palliative care only Only active treatments recorded
- Amivantamab with carboplatin and pemetrexed 0
- Cemiplimab with platinum-based chemotherapy 0
- Adagrasib 0
- Datopotamab deruxtecan 0
- Amivantamab with Lazertinib 0

Q2. Does your trust participate in any clinical trials for Non Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.

- None at the present time

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust